Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Status:
Withdrawn
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
A randomized phase II trial of FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL)
Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer.